Vitamin B6 catabolism and psoriasis risk: a cross-sectional study.

BACKGROUND

Psoriasis is a common autoimmune inflammatory disease. Vitamin B6 is crucial for the body's inflammatory response, yet the relationship between 4-pyridoxic acid (4-PA), pyridoxal 5'-phosphate (PLP) and vitamin B6 turnover (4-PA/PLP) in psoriasis remains unexplored.

OBJECTIVES

To investigate the relationship of 4-PA, PLP and vitamin B6 catabolism with the risk of psoriasis.

METHODS

This cross-sectional study analysed records for 7540 participants from the US National Health and Nutrition Examination Survey. Vitamin B6 catabolism was assessed via the serum 4-PA to PLP ratio (4-PA/PLP). The primary outcome was psoriasis, evaluated using weighted univariate and multivariate logistic regression to determine odds ratios (OR) and 95% confidence intervals (CI). Subgroup analyses were performed by age, gender, body mass index (BMI), hypertension, dyslipidaemia and cardiovascular disease.

RESULTS

Of the participants, 208 had psoriasis. After adjusting for confounders, 4-PA levels in the 'cutoff above' group were positively associated with psoriasis (OR 1.51, 95% CI 1.03-2.20). Additionally, 4-PA/PLP correlated with an increased psoriasis risk (OR 1.82, 95% CI 1.02-3.26). However, PLP levels did not show a significant association. The positive link between 4-PA/PLP and psoriasis was consistent in individuals with BMI ≥ 25 kg m-² and hypertension, and in those without dyslipidaemia.

CONCLUSIONS

The results revealed a significant association between 4-PA and 4-PA/PLP levels in the presence of psoriasis. However, further extensive prospective studies are necessary to establish causality.

© The Author(s) 2025. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].